Document Detail


Plasma C-peptide levels identify insulin-treated diabetic patients suitable for oral hypoglycaemic therapy.
MedLine Citation:
PMID:  6242818     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Plasma C-peptide levels were measured fasting and 2 h after an oral glucose load in 37 insulin-treated diabetic patients to assess their clinical value in identifying any noninsulin-dependent diabetic patients. All subjects were changed from insulin to oral hypoglycaemic therapy and followed for 3 months. Twenty patients (group A) completed the trial without requiring insulin and 17 (group B) required restabilization on insulin due to deteriorating metabolic control. Fasting and 2 h C-peptide levels were significantly higher in group A (0.11 +/- 0.09 and 0.17 +/- 0.12 nmol/l; mean +/- S.D.) compared with group B (0.02 +/- 0.03 and 0.02 +/- 0.03 nmol/l) (p less than 0.002 and p less than 0.002). The fasting C-peptide levels at 3 months (0.28 +/- 0.14 nmol/l) were also significantly higher than the fasting levels at the beginning of the study (p less than 0.002). Fasting and 2-h glucose levels were lower in group A (11.0 +/- 3.7 and 17.6 +/- 5.2 mmol/l) than in group B (14.4 +/- 6.2 and 23.1 +/- 5.9 mmol/l; p less than 0.05 and 0.02, respectively). The differences in glycosylated haemoglobin and fasting glucose levels at the start of the study and after 3 months of oral therapy were not statistically significant. Although C-peptide values overlapped in groups A and B, they were of greater value in identifying patients suitable for oral therapy than any single clinical criterion, and thus may help in identifying insulin-treated diabetic patients who may be treated with oral therapy without deterioration in metabolic control.
Authors:
P J Grant; E Barlow; D W Miles
Related Documents :
24722248 - Microrna-29 fine-tunes the expression of key foxa2-activated lipid metabolism genes and...
1782598 - Acute severe carbon monoxide exposure in the rat: effects of hyperglycemia and hypoglyc...
18614418 - The effect of magnesium supplementation on glucose and insulin levels of tae-kwan-do sp...
24308328 - The effects of resveratrol on flap survival in diabetic rats.
15647718 - Advances in diabetes for the millennium: new treatments for diabetic neuropathies.
7813808 - Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antago...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Diabetic medicine : a journal of the British Diabetic Association     Volume:  1     ISSN:  0742-3071     ISO Abbreviation:  Diabet. Med.     Publication Date:  1984 Nov 
Date Detail:
Created Date:  1988-01-22     Completed Date:  1988-01-22     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8500858     Medline TA:  Diabet Med     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  284-6     Citation Subset:  IM    
Affiliation:
Airedale General Hospital, Steeton, W. Yorkshire, U.K.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Blood Glucose / metabolism
C-Peptide / blood*
Diabetes Mellitus, Type 2 / blood*,  drug therapy
Fasting
Female
Humans
Hypoglycemic Agents / therapeutic use*
Insulin / therapeutic use*
Male
Middle Aged
Chemical
Reg. No./Substance:
0/Blood Glucose; 0/C-Peptide; 0/Hypoglycemic Agents; 11061-68-0/Insulin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The Whitehall Study: ten year follow-up report on men with impaired glucose tolerance with reference...
Next Document:  Urinary insulin excretion rate: an index of free insulinaemia in insulin-dependent diabetics.